# Indenoisoquinoline LMP400 for Advanced Solid Tumors and Lymphomas

> **NCT01794104** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 21 (actual)

## Conditions studied

- Neoplasm
- Lymphoma

## Interventions

- **DRUG:** LMP400

## Key facts

- **NCT ID:** NCT01794104
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02-15
- **Primary completion:** 2016-05-19
- **Final completion:** 2017-10-27
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2018-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01794104

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01794104, "Indenoisoquinoline LMP400 for Advanced Solid Tumors and Lymphomas". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01794104. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*